RETRACTED ARTICLE: Long non-coding XIAP-AS1 regulates cell proliferation, invasion and cell cycle in colon cancer

Abstract

Colon cancer is one of the most commonly diagnosed and deadly cancers worldwide. Further understanding of the biological mechanisms is important for exploring the molecular biomarkers and therapeutic targets of this disease. Dysregulation of long non-coding RNAs (lncRNAs) has been reported to be associated with the development and progression of various cancers. XIAP-AS1 is a novel lncRNA, which can regulate apoptosis in gastric cancer cells. However, the role of XIAP-AS1 in colorectal cancer (CRC) remains unclear. In this study, we found that XIAP-AS1 expression was significantly increased in CRC tissues and its expression showed a positive correlation with TNM stage and cumulative survival rate of CRC. To investigate whether XIAP-AS1 regulates the progression of CRC, we knocked down its expression in several CRC cell lines. CCK-8 assays showed that XIAP-AS1 knockdown remarkably suppressed CRC cell growth and arrested the cell cycle at the G0/G1 phase (flow cytometric analysis). Furthermore, XIAP-AS1 knockdown also remarkably blocked cell invasion of colon cancer cells by regulating the expression of EMT markers, such as E-cadherin, ZO-1, vimentin, and N-cadherin. Importantly, we found that XIAP-AS1 knockdown significantly reduced STAT3 phosphorylation. Overall, this study suggests that lncRNA XIAP-AS1 might serve as a potential oncogene for colon cancer.

Long noncoding RNA EPB41L4A‐AS1 functions as an oncogene by regulating the Rho/ROCK pathway in colorectal cancer

“…Approximately, 50% CRC patients present with metastasis at the time of diagnosis, or recurrence and metastasis after treatment (Chen et al, 2017). Therefore, an in‐depth understanding of the cellular and biological mechanisms of CRC may assist in exploring new therapeutic approaches (Lu, Yu, & Tan, 2019).…”

The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer

“…In contrast to the large body of evidence linking p53 and lncRNAs, only a handful of reports have clearly demonstrated an interplay between these RNA species and the other members of the p53 family. Notable examples are SNHG1 [157], which inhibits TAp63 via an uncharacterized mechanism leading to metastatic lung squamous cell carcinomas, and BLNCR [158] and XIAP-AS1 [159], two direct targets of ΔNp63 mediating its proliferative and invasive effects, respectively. Given the ever-growing interest in the lncRNA field, it is very likely that additional and surprising connections between lncRNAs and the p53 family will be unveiled in the near future.…”

“…One of the peptide-encoding circRNAs is the circular form of the p53-induced transcript PINT, whose peptide acts as a tumour suppressor in glioblastomas by binding to PAF1c, an RNA polymerase II associated factor, and inhibiting the transcriptional elongation of multiple oncogenic transcripts [169]. Another interesting circRNA WRAP53 promotes the translation of the p53 mRNA [151] XIAP-AS1 direct ΔNp63 target promoting cancer cell invasion [159] is the circular form of the lncRNA ANRIL. While, as described above, linear ANRIL affects p53 stability via ARF [141], circANRIL expression impairs rRNA processing and maturation, ultimately leading to nucleolar stress and p53 activation [170].…”

LINC00961 inhibits the migration and invasion of colon cancer cells by sponging miR‐223‐3p and targeting SOX11

“…Long noncoding RNAs (lncRNAs) are a vital group of noncoding RNA molecules that are longer than 200 nucleotides . The rapid development of RNA genomics has highlighted the oncogenic or anti‐oncogenic role of lncRNAs in colon cancer . SLCO4A1‐AS1 accelerates the colorectal cancer development through Wnt signaling pathway …”

“…6,7 The rapid development of RNA genomics has highlighted the oncogenic or anti-oncogenic role of lncRNAs in colon cancer. 8 SLCO4A1-AS1 accelerates the colorectal cancer development through Wnt signaling pathway. 9 lncRNA PVT1 facilitates the tumor progression in gallbladder cancer via the miR-143/HK2 axis.…”